Phase 2 N=20 Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Phase 2 N=43 CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Primary Mediastinal B-cell Lymphoma · Diffuse, Large B-cell Lymphoma · Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants
Phase 1 N=40 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
N/A N=13 Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Phase 2 N=8 Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
Anemia · Cancer Fatigue · Chronic Lymphocytic Leukemia
Primary: Treatment Success and Feasibility of Autologous Activated T-cells Infusion, Determined by Number of Participants That Achieved Target-Activated T-cell Dose Without DLT…
Phase 3 N=186 Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 0.9767 Proportion of Lymph Nodes
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Phase 1 N=54 A Study for Participants With Advanced Cancer
Advanced Cancer · Metastatic Cancer
Primary: Recommended Dose for Phase 2 Studies — 4.0; 6.0 mg/m²/day
N/A N=204 Lymph Node Mapping in Patients With Endometrial Cancer
Endometrial Cancer
Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients
Phase 2 N=73 Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Phase 2 N=14 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepatosplenic T-cell Lymphoma
Primary: Overall Response (OR) Rate — 0.07 Proportion of participants
Phase 2 N=16 Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
Colon Cancer · Rectal Cancer
Primary: Efficacy of Lymphoseek for Detection of Sentinel Nodes — 16 Participants
Phase 2 N=10 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
Lymphoma · T-Cell · Cutaneous
Primary: Response Rate — 0; 0; 1; 1 Participants
Phase 2 N=30 High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
Non-Hodgkin's Lymphoma · CNS Lymphoma
Primary: Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year — 28 Participants
N/A N=934 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
Breast Cancer
Primary: 5-year Disease-Free Survival — 84.4; 87.8 percentage of participants — p=0.004
N/A N=80 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection
Lymph Node Dissection · Lymphoedema · Lymphocoele
Primary: Postoperative Draining Time — 31; 32 days
Phase 1 N=63 A Dose-Escalation Study for Patients With Advanced Cancer
Advanced Cancer
Primary: Recommended Dose and Schedule for Phase 2 Studies — 8 mg/m^2/day
Phase 1 N=26 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
Phase 1 N=22 Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients
Carcinoma
Primary: the Number of Lymph Nodes: 1. Identified Within Each Lymph Node Group, 2.Located Within the Submandibular Gland, and 3. Within the Fibrofatty Contents Lying Deep to the…
Phase 2 N=90 Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer
Stage I Papillary Thyroid Cancer · Stage II Papillary Thyroid Cancer · Stage III Papillary Thyroid Cancer
Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…
Phase 3 N=28 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
Cervical Squamous Cell Carcinoma · Adenosquamous Carcinoma · Adenocarcinoma
Primary: Overall Survival Rate
Phase 2 N=108 Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes
Breast Cancer
Primary: Number of Participants With at Least One Treatment-related Adverse Event of Interest — 15; 20 Participants
Phase 2 N=17 Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Leukemia · Lymphoma
Primary: Survival at 1 Year After Transplantation — 10; 6 participants
Phase 2 N=59 Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Phase 2 N=65 Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)
Lymphoma, Non-Hodgkin
Primary: Progression-Free Survival (PFS) — 73 percentage of participants
Phase 2 N=26 Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
Mantle Cell Lymphoma · Lymphoma, Mantle Cell
Primary: Median Progression-free Survival (PFS) in Participants Treated With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R) — 23.5…
N/A N=18 Proton Therapy for Lymph Nodes in Breast Cancer
Breast Cancer
Primary: Volume of Heart Receiving ≥ 5 Gray (Gy)/Cobalt Gray Equivalent (CGE) — 34.7; 2.7 % of heart receiving >= 5 Gray (Gy) — p=0.0078
Phase 2 N=144 An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
Non-Hodgkin's Disease
Primary: Safety Analysis - Number of Participants With Dose Limiting Toxicities (DLT) in the DLT Evaluation Phase — 0; 0; 0 Participants